Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy
The purpose of the study is to evaluate the efficacy and safety of VX-548 in treating participants with PLSR.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Hope Research Institute
Phoenix, Arizona, United States
Arizona Research Center
Phoenix, Arizona, United States
Trovare Clinical Research
Bakersfield, California, United States
Velocity Clinical Research - Banning
Banning, California, United States
Velocity Clinical Research - San Diego
La Mesa, California, United States
Probe Clinical Research
Riverside, California, United States
Pain Management and Injury Relief
Thousand Oaks, California, United States
Visionary Investigators Network
Aventura, Florida, United States
Nature Coast Clinical Research - Crystal River
Crystal River, Florida, United States
JY Research Institute
Cutler Bay, Florida, United States
Start Date
December 13, 2023
Primary Completion Date
October 2, 2024
Completion Date
October 16, 2024
Last Updated
October 1, 2025
218
ACTUAL participants
VX-548
DRUG
Placebo
DRUG
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions